Tierney David S sold (to issuer) $12.1M of CPRX
Tierney David S sold (to issuer) 383,314 shares of CATALYST PHARMACEUTICALS, INC. (CPRX) at $31.50 ($12.07M total) on 2026-07-15.
How this was made
The 30-second read
Why it matters
The only new information is the director’s sale size, price, and post-transaction holdings (0 shares). Without additional company developments, the trading signal is mostly sentiment and positioning rather than fundamentals.
Market read
Traders may monitor CPRX for any follow-on insider activity or for whether the sale aligns with buyback mechanics, but there is no new fundamental driver here.
What to watch
No 10b5-1 plan is stated, which can increase speculation, but the filing still lacks any stated reason for the sale or any new company-specific catalyst.
Background
The article is a primary-source SEC Form 4 insider transaction for Catalyst Pharmaceuticals (CPRX).
Ticker impact
Catalyst Pharmaceuticals director Tierney David S sold 383,314 shares to the issuer at $31.50/share for about $12.07M, leaving 0 shares.
Likely limited near-term impact; traders may view it as routine liquidity or plan-related selling rather than a fundamental signal.
The Form 4 provides transaction size and price, but no 10b5-1 plan and no accompanying company news (earnings, guidance, trial, or deal) that would reprice fundamentals.
Market effects
No clear sector read-across because the article contains only an insider transaction, not a clinical or regulatory update.
None indicated.
None indicated.
Counterpoint
The sale is to the issuer (often buyback participation or similar mechanics), so it may not reflect bearish expectations about the business.
Key entities
- issuerCATALYST PHARMACEUTICALS, INC.
CPRX, the company whose director insider transaction is disclosed.
- insiderTierney David S
Director who sold 383,314 shares to the issuer at $31.50/share.